RESOURCES

RESEARCH AREA: Autoimmune Cardiovascular Disease Cell and Gene Therapy Infectious Disease Metabolism Neurology Oncology Other Rare Disease Respiratory Disease

May 20, 2026

Advancing In Vivo CAR-T Therapies: Preclinical Evaluation Strategies and Models

In recent years, CAR-T therapy has achieved significant breakthroughs in the treatment of hematological malignancies. However, conventional ex vivo CAR-T approaches require cell isolation, genetic modification, expansion, and reinfusion, resulting in a lengthy, complex, and costly manufacturing process. These limitations have hindered broader clinical development. To address these challenges, in vivo CAR-T has emerged as a promising next-generation cell therapy approach. This strategy enables the direct induction of CAR expression in target immune cells in vivo via delivery systems, thereby generating cytotoxic CAR effector cells within the body. Compared with traditional approaches, in vivo CAR-T offers advantages in simplified manufacturing, improved accessibility, and enhanced scalability.
May 18, 2026

Beyond the Eosinophilic Paradigm: Mechanism-Driven Selection of Mouse Models in Asthma Research

Asthma affects more than 300 million people worldwide and remains one of the most complex chronic inflammatory disorders of the airways. To empower precise, mechanism-of-action (MoA) driven drug discovery, GemPharmatech has developed a comprehensive asthma model matrix. We categorize our models based on two key clinical parameters: responsiveness to glucocorticoids and predominant immune cell infiltration. This matrix allows you to strategically select the most suitable model based on your drug’s MoA. For developers of a follow-on therapeutic targeting T2 asthma, benchmarking against Dupilumab's near-perfect efficacy in our HDM model is the recommended approach. For those targeting the unmet non-T2 space, our steroid-resistant, neutrophil-dominant asthma models provide a clinically relevant platform to demonstrate true differentiation.
March 24, 2026

Accelerating T-Cell Engager (TCE) Development: Advanced Preclinical Evaluation Solutions

In recent years, the landscape of cancer immunotherapy has undergone a paradigm shift across diverse oncological indications. However, achieving robust efficacy in solid tumors remains a significant challenge, often due to downregulated MHC molecules or insufficient immune cell infiltration within the tumor microenvironment (TME). While autologous CAR-T cell therapies offer potent cytotoxicity, their widespread adoption is frequently hampered by lengthy manufacturing timelines, high production costs, and the complexities of personalized medicine.
March 18, 2026

Advancing Antifungal Drug Development with Preclinical Fungal Infection Platform

GemPharmatech's BSL-2 biosafety laboratory maintains a comprehensive library of clinically relevant fungal strains, including Candida albicans, Candida auris, Aspergillus fumigatus, and Aspergillus flavus. Our team has established validated systems for fungal culture, murine infection modeling, and multi-endpoint readout detection. Our established models — spanning fungal sepsis, invasive pulmonary aspergillosis, and cutaneous fungal infection — have been successfully deployed to support efficacy evaluation of multiple antifungal compounds, delivering robust and reliable data.
March 09, 2026

Advancing Heart Failure Research: A Comprehensive Guide to Preclinical HFrEF and HFpEF Models

Heart failure (HF) remains a global healthcare crisis, with two distinct phenotypes—Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF)—posing unique challenges for drug development and translational research. To accelerate breakthroughs, robust preclinical models that recapitulate human disease pathophysiology are essential. Below, we break down a curated panel of validated HFrEF and HFpEF models, designed to empower researchers in selecting the right tool for their studies.
March 05, 2026

Beyond Weight Loss: A New Paradigm in Anti-Obesity Drug Evaluation

As an innovator in laboratory animal models, GemPharmatech provides high-quality genetically engineered rodent models and comprehensive technical services to academic institutions and pharmaceutical companies worldwide. Our portfolio includes diet-induced obesity (DIO) models and related metabolic disease models in both mice and rats, enabling robust simulation of human metabolic disorders. Through advanced gene-editing technologies, we provide drug target humanized models to facilitate mechanistic exploration of anti-obesity therapeutics. In addition, we offer integrated services including body composition analysis and energy metabolism assessment, enabling precise evaluation of drug effects across adipose tissue, skeletal muscle, and multiple metabolic organs. From model selection to data interpretation, we provide end-to-end solutions to accelerate translational research.
February 09, 2026

GemPharmatech Mouse Models Support Discovery in Cell Publication: Revealing a Novel Treg-Mediated Mechanism of Immunotherapy Resistance

GemPharmatech’s models were used in a publication accepted by the prestigious journal Cell. The study reveals a fundamental new mechanism of tumor immune evasion. It demonstrates that tumor-produced ammonia is metabolically utilized by regulatory T cells (Tregs), enhancing their immunosuppressive capacity and driving resistance to treatment. In cancer immunotherapy, understanding how metabolic byproducts in the tumor microenvironment (TME) influence immune cells is a central focus. Read the blog to learn how GemPharmatech's mouse models were instrumental in this research.
January 29, 2026

Advancing PVR Research: A Novel Transgenic Mouse Model with Spontaneous Disease Phenotype

Proliferative Vitreoretinopathy (PVR) is the formation of scar tissue in the eye after complication of retinal detachment or eye injury. At present, the therapeutic approaches for PVR are limited, with surgery still serving as the core treatment. Based on years of experience in transgenic mouse research and development, GemPharmatech has developed a novel B6-Rho-hVEGFA-Tg transgenic mouse model. By 4 weeks of age, it exhibits typical ocular pathological features, including abnormal retinal neovascularization, retinal structural detachment, and formation of proliferative membranes, thereby serving as a novel tool for research on proliferative vitreoretinopathy (PVR) and other related neovascular ophthalmic diseases.
December 15, 2025

Fabry Disease Mouse Models for Preclinical Efficacy Evaluation

Fabry disease (FD) is a rare, progressive, X-linked inherited disorder caused by deficient or absent lysosomal α-galactosidase A (α-GAL) activity, leading to impaired glycosphingolipid metabolism. To accelerate FD research and help researchers better understand disease mechanisms and develop new treatments, GemPharmatech has developed two GLA gene knockout mouse models: Gla-KO and NCG-Gla-KO.

LEARN MORE